Abstract | BACKGROUND: OBJECTIVES: The aim of this review was to determine the efficacy and safety of muscle relaxants in pain management in patients with RA. The muscle relaxants that were included in this review are the antispasmodic benzodiazepines ( alprazolam, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, cloxazolam, clorazepate, diazepam, estazolam, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, pinazepam, prazepam, quazepam, temazepam, tetrazepam, triazolam), antispasmodic non- benzodiazepines ( cyclobenzaprine, carisoprodol, chlorzoxazone, meprobamate, methocarbamol, metaxalone, orphenadrine, tizanidine and zopiclone), and antispasticity drugs ( baclofen and dantrolene sodium). SEARCH METHODS: We performed a search of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 4th quarter 2010), MEDLINE (1950 to week 1 November 2010), EMBASE (Week 44 2010), and PsycINFO (1806 to week 2 November 2010). We also searched the 2008 to 2009 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) abstracts and performed a handsearch of reference lists of relevant articles. SELECTION CRITERIA: We included randomised controlled trials which compared a muscle relaxant to another therapy (active, including non-pharmacological therapies, or placebo) in adult patients with RA and that reported at least one clinically relevant outcome. DATA COLLECTION AND ANALYSIS: Two blinded review authors independently extracted data and assessed the risk of bias in the trials. Meta-analyses were used to examine the efficacy of muscle relaxants on pain, depression, sleep and function, as well as their safety. MAIN RESULTS: Six trials (126 participants) were included in this review. All trials were rated at high risk of bias. Five cross-over trials evaluated a benzodiazepine, four assessed diazepam (n = 71) and one assessed triazolam (n = 15). The sixth trial assessed zopiclone (a non- benzodiazepine) (n = 40) and was a parallel group study. No trial duration was longer than two weeks while three single dose trials assessed outcomes at 24 hours only. Overall the included trials failed to find evidence of a beneficial effect of muscle relaxants over placebo, alone (at 24 hrs, 1 or 2 weeks) or in addition to non-steroidal anti-inflammatory drugs ( NSAIDs) (at 24 hrs), on pain intensity, function, or quality of life. Data from two trials of longer than 24 hours duration (n = 74) ( diazepam and zopiclone) found that participants who received a muscle relaxant had significantly more adverse events compared with those who received placebo (number needed to harm (NNTH) 3, 95% CI 2 to 7). These were predominantly central nervous system side effects, including dizziness and drowsiness (NNTH 3, 95% CI 2 to 11). AUTHORS' CONCLUSIONS: Based upon the currently available evidence in patients with RA, benzodiazepines ( diazepam and triazolam) do not appear to be beneficial in improving pain over 24 hours or one week. The non- benzodiazepine agent zopiclone also did not significantly reduce pain over two weeks. However, even short term muscle relaxant use (24 hours to 2 weeks) is associated with significant adverse events, predominantly drowsiness and dizziness.
|
Authors | Bethan L Richards, Samuel L Whittle, Rachelle Buchbinder |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Vol. 1
Pg. CD008922
(Jan 18 2012)
ISSN: 1469-493X [Electronic] England |
PMID | 22258993
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Azabicyclo Compounds
- Muscle Relaxants, Central
- Piperazines
- zopiclone
- Sulindac
- Triazolam
- Diazepam
- Indomethacin
|
Topics |
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Arthralgia
(drug therapy, etiology)
- Arthritis, Rheumatoid
(complications, drug therapy)
- Azabicyclo Compounds
(adverse effects, therapeutic use)
- Diazepam
(adverse effects, therapeutic use)
- Humans
- Indomethacin
(therapeutic use)
- Muscle Relaxants, Central
(adverse effects, therapeutic use)
- Pain Management
(methods)
- Piperazines
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Sulindac
(therapeutic use)
- Triazolam
(adverse effects, therapeutic use)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|